569 related articles for article (PubMed ID: 17662645)
1. Tissue transglutaminase-mediated chemoresistance in cancer cells.
Verma A; Mehta K
Drug Resist Updat; 2007; 10(4-5):144-51. PubMed ID: 17662645
[TBL] [Abstract][Full Text] [Related]
2. Transglutaminase 2: a multi-tasking protein in the complex circuitry of inflammation and cancer.
Mehta K; Kumar A; Kim HI
Biochem Pharmacol; 2010 Dec; 80(12):1921-9. PubMed ID: 20599779
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer.
Mehta K; Fok J; Miller FR; Koul D; Sahin AA
Clin Cancer Res; 2004 Dec; 10(23):8068-76. PubMed ID: 15585642
[TBL] [Abstract][Full Text] [Related]
4. Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-kappaB activity in hypoxic tumor cells.
Jang GY; Jeon JH; Cho SY; Shin DM; Kim CW; Jeong EM; Bae HC; Kim TW; Lee SH; Choi Y; Lee DS; Park SC; Kim IG
Oncogene; 2010 Jan; 29(3):356-67. PubMed ID: 19838207
[TBL] [Abstract][Full Text] [Related]
5. Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells.
Herman JF; Mangala LS; Mehta K
Oncogene; 2006 May; 25(21):3049-58. PubMed ID: 16449978
[TBL] [Abstract][Full Text] [Related]
6. Transglutaminase-2: evolution from pedestrian protein to a promising therapeutic target.
Agnihotri N; Mehta K
Amino Acids; 2017 Mar; 49(3):425-439. PubMed ID: 27562794
[TBL] [Abstract][Full Text] [Related]
7. Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy.
Yuan L; Siegel M; Choi K; Khosla C; Miller CR; Jackson EN; Piwnica-Worms D; Rich KM
Oncogene; 2007 Apr; 26(18):2563-73. PubMed ID: 17099729
[TBL] [Abstract][Full Text] [Related]
8. The role of tissue transglutaminase (TG2) in regulating the tumour progression of the mouse colon carcinoma CT26.
Kotsakis P; Wang Z; Collighan RJ; Griffin M
Amino Acids; 2011 Oct; 41(4):909-21. PubMed ID: 21046178
[TBL] [Abstract][Full Text] [Related]
9. Tissue transglutaminase in tumour progression: friend or foe?
Kotsakis P; Griffin M
Amino Acids; 2007 Aug; 33(2):373-84. PubMed ID: 17581697
[TBL] [Abstract][Full Text] [Related]
10. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
Carbone C; Di Gennaro E; Piro G; Milone MR; Pucci B; Caraglia M; Budillon A
Amino Acids; 2017 Mar; 49(3):517-528. PubMed ID: 27761756
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway.
Mann AP; Verma A; Sethi G; Manavathi B; Wang H; Fok JY; Kunnumakkara AB; Kumar R; Aggarwal BB; Mehta K
Cancer Res; 2006 Sep; 66(17):8788-95. PubMed ID: 16951195
[TBL] [Abstract][Full Text] [Related]
12. Transglutaminase 2 and NF-kappaB interplay during NGF-induced differentiation of neuroblastoma cells.
Condello S; Caccamo D; Currò M; Ferlazzo N; Parisi G; Ientile R
Brain Res; 2008 May; 1207():1-8. PubMed ID: 18374307
[TBL] [Abstract][Full Text] [Related]
13. The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer.
Ai L; Kim WJ; Demircan B; Dyer LM; Bray KJ; Skehan RR; Massoll NA; Brown KD
Carcinogenesis; 2008 Mar; 29(3):510-8. PubMed ID: 18174247
[TBL] [Abstract][Full Text] [Related]
14. Glucosamine is an effective chemo-sensitizer via transglutaminase 2 inhibition.
Kim DS; Park KS; Jeong KC; Lee BI; Lee CH; Kim SY
Cancer Lett; 2009 Jan; 273(2):243-9. PubMed ID: 18804908
[TBL] [Abstract][Full Text] [Related]
15. Tissue transglutaminase promotes or suppresses tumors depending on cell context.
Chhabra A; Verma A; Mehta K
Anticancer Res; 2009 Jun; 29(6):1909-19. PubMed ID: 19528447
[TBL] [Abstract][Full Text] [Related]
16. Transglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival.
Fisher ML; Keillor JW; Xu W; Eckert RL; Kerr C
Mol Cancer Res; 2015 Jul; 13(7):1083-94. PubMed ID: 25934691
[TBL] [Abstract][Full Text] [Related]
17. Implications of tissue transglutaminase expression in malignant melanoma.
Fok JY; Ekmekcioglu S; Mehta K
Mol Cancer Ther; 2006 Jun; 5(6):1493-503. PubMed ID: 16818508
[TBL] [Abstract][Full Text] [Related]
18. Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2.
Choi K; Siegel M; Piper JL; Yuan L; Cho E; Strnad P; Omary B; Rich KM; Khosla C
Chem Biol; 2005 Apr; 12(4):469-75. PubMed ID: 15850984
[TBL] [Abstract][Full Text] [Related]
19. Tissue transglutaminase (TG2) acting as G protein protects hepatocytes against Fas-mediated cell death in mice.
Sarang Z; Molnár P; Németh T; Gomba S; Kardon T; Melino G; Cotecchia S; Fésüs L; Szondy Z
Hepatology; 2005 Sep; 42(3):578-87. PubMed ID: 16108039
[TBL] [Abstract][Full Text] [Related]
20. Transglutaminase 2 limits murine peritoneal acute gout-like inflammation by regulating macrophage clearance of apoptotic neutrophils.
Rose DM; Sydlaske AD; Agha-Babakhani A; Johnson K; Terkeltaub R
Arthritis Rheum; 2006 Oct; 54(10):3363-71. PubMed ID: 17009310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]